Standard Biotools Inc. last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $20.1 million (-7.6% year over year) and diluted EPS of -$0.07. It usually reports 8–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
20
-7.6%
|
-27
+20.0%
|
-0.07
+22.2%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
21
+4.6%
|
127
+588.1%
|
0.33
+571.4%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
24
-4.0%
|
19
+156.6%
|
0.05
+155.0%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
20
-11.5%
|
-35
-7.9%
|
-0.09
-28.6%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
22
-3.2%
|
-33
+26.8%
|
-0.09
+25.0%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
20
|
-26
|
-0.07
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
25
-12.1%
|
-34
-72.3%
|
-0.09
+63.3%
|
|
Oct 30, 2024
30 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1162194
- Former names
- FLUIDIGM CORP (until Apr 1, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.